At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX
In Brief
A Phase 2 clinical trial evaluating aprepitant, dexamethasone, and 6 other interventions for Colorectal Cancer and Nausea and Vomiting. Completed, enrolled 54 participants across 6 sites.
Detailed Summary
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
Study Details
Timeline
Interventions
Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
as per institutional standard of care
as per institutional standard of care
as per institutional standard of care
as per institutional standard of care
Palonosetron 0.25 mg IV push on day 1 only.
baseline